ALK and cancer: Evidences from genetic manipulation studies show GSTP1 facilitates cell viability and increases resistance to cisplatin and targeted therapy including gefitinib, erlotinib, or afatinib for the relevant EGFR mutated, and crizotinib for ALK translocated cancers.